Lyntonix
- Academic, tech transfer
- Biotech or pharma, therapeutic R&D
The vision of Lyntonix is to provide effective and safe medications for chronic pain that currently is an unmet need. We are looking for co-development partners for our preclinical drug candidate LTX-568, which is a first-in-class drug for irritable bowel syndrome (IBS). We plan to start out-licensing in 2027 after completing phase I and/or IIa clinical trials.
Address
TaipeiTaiwan
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}